A Phase 1/2 Dose-Ranging Safety and Immunogenicity Study of mRNA-Based Candidate Pandemic Influenza Vaccines in Healthy Adults
Clinical Infectious Diseases · 2026
DOI: 10.1093/cid/ciag278 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Catherine A Cosgrove und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Infection and Immunity & Vaccine Institute, City St George's, University of London, United Kingdom & St George's University Hospital NHS…. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza, Human, Immunogenicity, Vaccine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Moderna, Inc.
Abstract (Originalsprache)
Background
Influenza A viruses pose a persistent pandemic threat. We report safety, reactogenicity, and immunogenicity findings for mRNA-1018 pandemic influenza vaccine candidates from a phase 1/2 study in healthy adults.
Methods
In part A, participants were randomized to receive 1 of 4 mRNA-1018 candidates at 1 of 3 dose levels across 2 influenza A groups: (1) H5N8/H5-only or (2) H7N9/H7-only. Part B participants were randomized to receive H5-only-CG. The primary objectives were to evaluate the safety and reactogenicity. The secondary objectives included evaluation of humoral immunogenicity through day 205 by hemagglutination inhibition (HAI), neuraminidase inhibition, and microneutralization assays.
Results
Parts A and B comprised 1195 and 304 dosed participants, respectively. Overall, solicited local adverse reactions (ARs) within 7 days of vaccination occurred in 76.8% of participants across vaccine candidates and dose levels, most commonly injection-site pain. Solicited systemic ARs were reported in 62.8% of participants, most frequently fatigue and headache. Postvaccination immune responses, assessed absolutely, by HAI titers and dynamically, by seroconversion rates, tended to increase with vaccine dose. H5-based candidates induced stronger strain-specific HAI.
Conclusions
Vaccine candidates were sufficiently well tolerated and immunogenic. Further development of mRNA pandemic influenza vaccines is warranted. Clinical Trials Registration. NCT05972174
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Infection and Immunity & Vaccine Institute, City St George's, University of London, United Kingdom & St George's University Hospital NHS Trust, London, United Kingdom.
- Clinical Operations and Clinical Biomarkers, Moderna, Inc., Cambridge, Massachusetts, USA.
ORCID-Profile: Catherine A Cosgrove, Seun Osibajo
Förderung
- Moderna, Inc
Zitieren
APA
Cosgrove, C. A., Avanesov, A., Rust, D., Osibajo, S., Kang, K., Leav, B., & ODYSSEY Study Group (2026). A Phase 1/2 Dose-Ranging Safety and Immunogenicity Study of mRNA-Based Candidate Pandemic Influenza Vaccines in Healthy Adults. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag278
Vancouver
Cosgrove CA, Avanesov A, Rust D, Osibajo S, Kang K, Leav B, et al. A Phase 1/2 Dose-Ranging Safety and Immunogenicity Study of mRNA-Based Candidate Pandemic Influenza Vaccines in Healthy Adults. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag278
BibTeX
@article{Cosgrove2026,
author = {Cosgrove, Catherine A and Avanesov, Andrei and Rust, Dondi and Osibajo, Seun and Kang, Kingston and Leav, Brett and ODYSSEY Study Group, ODYSSEY Study Group},
title = {A Phase 1/2 Dose-Ranging Safety and Immunogenicity Study of mRNA-Based Candidate Pandemic Influenza Vaccines in Healthy Adults},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciag278}
}
EUVIMED